The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

Dettagli Bibliografici
Autori principali:	Barnett, G, Flashman, E, Kelly, D, Schofield, C, Gershlick, A
Natura:	Conference item
Pubblicazione:	2013

Documenti analoghi

74 Pro-Angiogenic Effects of the Prolyl-hydroxylase Inhibitor FG-2216/BIQ: Therapeutic Angiogenesis for the Treatment of Chronic Total Occlusions.
di: Barnett, G, et al.
Pubblicazione: (2014)

Pro-angiogenic effects of proly-hydroxylase inhibitor FG-2216 and potential for use in a novel strategy of therapeutic angiogenesis for difficult cases of coronary total occlusion
di: Barnett, G, et al.
Pubblicazione: (2014)

Enhanced Endothelial Tubule Formation in Response to Proly-Hydroxylase Inhibitor FG-2216: A Step Towards Therapeutic Angiogenesis in Chronic Total Occlusions
di: Barnett, G, et al.
Pubblicazione: (2012)

Regulation of HIF: prolyl hydroxylases.
di: Stolze, I, et al.
Pubblicazione: (2006)

The use of dioxygen by HIF prolyl hydroxylase (PHD1).
di: McNeill, L, et al.
Pubblicazione: (2002)

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.
di: Tuckerman, JR, et al.
Pubblicazione: (2004)

2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.
di: Mole, D, et al.
Pubblicazione: (2003)

Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.
di: Schlemminger, I, et al.
Pubblicazione: (2003)

Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase inhibitors in Clinical Trials
di: Yeh, TL, et al.
Pubblicazione: (2017)

Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents.
di: Flashman, E, et al.
Pubblicazione: (2010)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
di: Cockman, M, et al.
Pubblicazione: (2019)

Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
di: Chowdhury, R, et al.
Pubblicazione: (2016)

Tuning the transcriptional response to hypoxia by inhibiting HIF prolyl- and asparaginyl-hydroxylases
di: Chan, M, et al.
Pubblicazione: (2016)

Tissue expression and functional insights into HIF prolyl hydroxylase domain enzymes
di: Wijeyekoon, JB
Pubblicazione: (2013)

Structural, biochemical and inhibition studies on hypoxia-inducible factor (HIF) prolyl hydroxylases
di: Lippl, K
Pubblicazione: (2018)

HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels.
di: Masson, N, et al.
Pubblicazione: (2003)

Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.
di: Chowdhury, R, et al.
Pubblicazione: (2013)

Prolyl hydroxylases and therapeutics.
di: Smith, T, et al.
Pubblicazione: (2010)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice.
di: Chen, R, et al.
Pubblicazione: (2014)

Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation.
di: Tian, Y, et al.
Pubblicazione: (2006)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice
di: Chen, R, et al.
Pubblicazione: (2014)

The HIF prolyl hydroxylase PHD3 is a potential substrate of the TRiC chaperonin.
di: Masson, N, et al.
Pubblicazione: (2004)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase, and is sensitive to off target inhibition by prolyl hydroxylase domain inhibitors that stabilise Hypoxia Inducible Factor
di: Kiriakidis, S, et al.
Pubblicazione: (2017)

Mutation Analysis of HIF-prolyl hydroxylases (PHD/EGLN) in Inherited Phaeochromocytoma and Renal Cell Carcinoma
di: Astuti, D, et al.
Pubblicazione: (2010)

Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
di: Holt-Martyn, JP, et al.
Pubblicazione: (2019)

Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.
di: Yeoh, K, et al.
Pubblicazione: (2013)

A fluorescent benzo[g]isoquinoline-based HIF prolyl hydroxylase inhibitor for cellular imaging
di: Mayer, M, et al.
Pubblicazione: (2018)

Kinetic investigations of the oxygen entry pathway of the hypoxia-inducible factor (HIF) prolyl hydroxylase 2
di: Kearney, L
Pubblicazione: (2015)

Substrate selectivity of prolyl hydroxylases
di: McDonough, M
Pubblicazione: (2018)

BIOL 56-ESI-MS studies on prolyl hydroxylase domain 2
di: Mecinovic, J, et al.
Pubblicazione: (2008)

Studies on HIF hydroxylases
di: Webb, J
Pubblicazione: (2008)

HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation.
di: Willam, C, et al.
Pubblicazione: (2006)

The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.
di: Foxler, D, et al.
Pubblicazione: (2012)

Structural and mechanistic studies on prolyl hydroxylases
di: Chowdhury, R
Pubblicazione: (2008)

Inhibition of a viral prolyl hydroxylase
di: Langley, G, et al.
Pubblicazione: (2019)

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.
di: Astuti, D, et al.
Pubblicazione: (2011)

Use of mass spectrometry to probe the nucleophilicity of cysteinyl residues of prolyl hydroxylase domain 2.
di: Mecinović, J, et al.
Pubblicazione: (2009)

Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen.
di: Flashman, E, et al.
Pubblicazione: (2010)

Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen.
di: Flashman, E, et al.
Pubblicazione: (2010)

Oxygen sensing by HIF hydroxylases.
di: Schofield, C, et al.
Pubblicazione: (2004)